TMS Co., Ltd. Stock

Equities

4891

JP3544960002

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-05-01 EDT 5-day change 1st Jan Change
259 JPY +5.28% Intraday chart for TMS Co., Ltd. +9.75% +37.77%

Financials

Sales 2024 * 700M 4.45M 6.13M Sales 2025 * - Capitalization 10.44B 66.39M 91.43M
Net income 2024 * -80M -509K -701K Net income 2025 * -1.28B -8.11M -11.17M EV / Sales 2024 * 14.9 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-118 x
P/E ratio 2025 *
-8.09 x
Employees 14
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.27%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Jefferies Adjusts TMS’ Price Target to 760 Yen From 730 Yen, Keeps at Buy MT
Tennant Minerals Raises AU$4.8 Million for Drilling, Target Testing; Shares Down 4% MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Tennant Minerals Finds 23% Copper Concentrate, 1.5G/T Gold at Bluebird Project MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise MT
Tennant Minerals to Commence Next Phase of Drilling at Barkly Project; Shares Down 3% MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in Japan CI
More news
1 day+5.28%
1 week+9.75%
Current month-7.83%
1 month-4.78%
3 months-6.50%
Current year+37.77%
More quotes
1 week
232.00
Extreme 232
262.00
1 month
223.00
Extreme 223
280.00
Current year
171.00
Extreme 171
367.00
1 year
159.00
Extreme 159
460.00
3 years
159.00
Extreme 159
1 188.00
5 years
159.00
Extreme 159
1 188.00
10 years
159.00
Extreme 159
1 188.00
More quotes
Managers TitleAgeSince
Founder 66 05-02-16
President 57 11-04-30
Chief Administrative Officer 54 18-01-31
Members of the board TitleAgeSince
President 57 11-04-30
Director/Board Member 70 21-04-30
Director/Board Member 60 20-02-29
More insiders
Date Price Change Volume
24-05-01 259 +5.28% 256 300
24-04-30 246 +4.24% 110,800
24-04-26 236 -0.42% 133,900
24-04-25 237 -3.66% 194,400
24-04-24 246 +4.24% 172,800

Delayed Quote Japan Exchange, May 01, 2024 at 02:00 am

More quotes
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
259 JPY
Average target price
760 JPY
Spread / Average Target
+193.44%
Consensus

Annual profits - Rate of surprise